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Abstract
Context—Goal-directed resuscitation for severe sepsis and septic shock has been reported to
reduce mortality when applied in the emergency department.
Objective—To test the hypothesis of noninferiority between lactate clearance and central venous
oxygen saturation (ScvO2) as goals of early sepsis resuscitation.
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Design, Setting, and Patients—Multicenter randomized, noninferiority trial involving
patients with severe sepsis and evidence of hypoperfusion or septic shock who were admitted to
the emergency department from January 2007 to January 2009 at 1 of 3 participating US urban
hospitals.
Interventions—We randomly assigned patients to 1 of 2 resuscitation protocols. The ScvO2
group was resuscitated to normalize central venous pressure, mean arterial pressure, and ScvO2 of
at least 70%; and the lactate clearance group was resuscitated to normalize central venous
pressure, mean arterial pressure, and lactate clearance of at least 10%. The study protocol was
continued until all goals were achieved or for up to 6 hours. Clinicians who subsequently assumed
the care of the patients were blinded to the treatment assignment.
Main Outcome Measure—The primary outcome was absolute in-hospital mortality rate; the
noninferiority threshold was set at Δ equal to −10%.
Results—Of the 300 patients enrolled, 150 were assigned to each group and patients were well
matched by demographic, comorbidities, and physiological features. There were no differences in
treatments administered during the initial 72 hours of hospitalization. Thirty-four patients (23%) in
the ScvO2 group died while in the hospital (95% confidence interval [CI], 17%–30%) compared
with 25 (17%; 95% CI, 11%–24%) in the lactate clearance group. This observed difference
between mortality rates did not reach the predefined −10% threshold (intent-to-treat analysis: 95%
CI for the 6% difference, −3% to 15%). There were no differences in treatment-related adverse
events between the groups.
Conclusion—Among patients with septic shock who were treated to normalize central venous
and mean arterial pressure, additional management to normalize lactate clearance compared with
management to normalize ScvO2 did not result in significantly different in-hospital mortality.
The rate of severe sepsis hospitalizations has doubled during the last decade with estimates
indicating that at least 750 000 persons are affected annually in the United States.1–3
Approximately, 500 000 patients with severe sepsis in the United States annually are
initially treated in emergency departments.4 The Surviving Sepsis Campaign international
consensus guidelines recommend protocol-driven treatment that uses quantitative
resuscitation for emergency department patients with severe sepsis and septic shock.5
Quantitative resuscitation refers to the use of an explicit protocol that targets predefined
physiological or laboratory goals to be achieved within the first several hours. This concept
was pioneered by Shoemaker et al6 to treat high-risk surgical patients. Results of a recent
meta-analysis indicated a survival benefit associated with the use of an early and
quantitative resuscitation strategy applied to heterogeneous populations of patients with
sepsis.7
The optimal goals for quantitative resuscitation of sepsis remain uncertain. It is generally
accepted that hemodynamic targets should include some measure of the adequacy of cardiac
pre-load, such as central venous pressure, and perfusion pressure, such as mean arterial
pressure.8 A more controversial issue is the method of determining tissue oxygen delivery.
Citing a single-center study, the Surviving Sepsis Campaign guidelines recommend the use
of central venous oxygen saturation (ScvO2) or mixed venous oxygen saturation to assess
the balance of tissue oxygen delivery and consumption9; however, since its publication in
2001 a substantial amount of controversy about this single-center study has been generated
in the scientific community.10–12 Additionally, recently published practice surveys have
indicated that the time, expertise, and specialized equipment required to measure ScvO2
collectively pose a major barrier to the implementation of protocol-driven quantitative
resuscitation programs.13,14 In contrast, lactate clearance, derived from calculating the
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change in lactate concentration from 2 blood specimens drawn at different times, potentially
represents a more accessible method to assess tissue oxygen delivery.15,16
To address the potential utility of lactate clearance as a substitute for ScvO2, we conducted a
multicenter, randomized trial among patients presenting to the emergency department with
severe sepsis and septic shock, with the primary hypothesis that early resuscitation targeting
lactate clearance as the marker of adequacy of oxygen delivery was noninferior to the
currently recommended ScvO2 monitoring for the outcome of in-hospital mortality.
METHODS
Study Design
This study was a prospective randomized, parallel group, nonblinded, clinical trial designed
to assess the noninferiority of lactate clearance vs ScvO2 as the protocol goal that evaluated
adequacy of oxygen delivery during early quantitative resuscitation of severe sepsis and
septic shock. The trial took place from January 2007 to January 2009 in the emergency
departments of 3 large urban medical centers in the United States. The research protocol was
approved by the local institutional review boards and performed in accordance with Good
Clinical Practice guidelines.
Participants
Patients with severe sepsis or septic shock were assessed for inclusion, which required that
patients be older than 17 years with confirmed or presumed infection, have 2 or more
systemic inflammatory response criteria,17 and have hypoperfusion evidenced by either a
systolic blood pressure lower than 90 mm Hg after a minimum of 20 mL/kg rapid volume
challenge or a blood lactate concentration of at least 36 mg/dL (4 mmol/L). The criteria for
exclusion from the study were pregnancy, any primary diagnosis other than sepsis,
suspected requirement for immediate surgery within 6 hours of diagnosis, an absolute
contraindication to chest or neck central venous catheterization, cardiopulmonary
resuscitation, transfer from another institution with a sepsis-specific resuscitative therapy
underway, and advanced directive orders that would restrict the study procedure. Using a
24-hour day, 7-day-week method that was previously established for the routine clinical care
of sepsis patients at each of the participating institutions, an alert was sent to inform clinical
care resources when patients were identified as candidates for early aggressive resuscitation.
This alert was also received by study staff who responded and screened the patients for
study enrollment. Each enrolled patient or the patient’s legally authorized next of kin
provided written informed consent prior to collection of data. Patients or family members
self-identified their race.
Treatment Assignment
Patients were randomly assigned to 1 of 2 groups (eFigure, available at
http://www.jama.com). Each group received structured quantitative resuscitation while in
the emergency department. The ScvO2 group was resuscitated by sequentially providing
therapy needed to meet thresholds of central venous pressure, followed by mean arterial
pressure, and then ScvO2. The lactate clearance group had similarly targeted thresholds in
central venous pressure, followed by mean arterial pressure, and then lactate clearance
instead of ScvO2. Standard measures were used to ensure appropriate concealment of group
assignment until after informed consent was obtained. The group assignment sequence was
generated by an independent statistician using a parallel design, balanced randomization
schedule (1:1 ratio of cases and controls), using the PROC PLAN function in SAS
incorporating a sample size of 300, block size equal to 10, with a seed of 6 457 149 (SAS
Institute Inc, Cary, North Carolina). After written informed consent was obtained, study
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staff opened an opaque sealed envelope containing the randomization assignment. Study
staff then enforced the study protocol. By design, the clinical staff in the emergency
departments could not be blinded to group assignment; however, the clinical staff
(physicians and nurses) who assumed subsequent care of the patients in the intensive care
units (ICUs) were unaware of group assignment. Prior to entry in the study, patients were
cared for by emergency physicians, who provided basic care processes according to
participating institutional standards.
Treatment Interventions
Appropriate specimens were taken for culture, and antibiotics were administered as soon as
practical. Blood pressure was monitored by either noninvasive automated cuff
sphygmomanometer or arterial catheter according to the clinical team’s preference. All
patients received chest or neck central venous catheter capable of measuring continuous
ScvO2 (PreSep, Edwards Lifesciences, Irvine, California).
Patients randomized to the ScvO2 group had their central venous catheters connected to a
computerized spectrophotometer (Edwards Lifesciences) that displayed continuous ScvO2
readings. The patients were then cared for according to the prespecified treatment plan.
First, isotonic crystalloid was administered in boluses to achieve a central venous pressure
of 8 mm Hg or higher. Second, the mean arterial pressure goal of 65 mm Hg or higher, if not
achieved with fluid administration, was targeted by initiating and titrating vasopressors
(dopamine or norepinephrine) to achieve this desired blood pressure goal. Finally, the ScvO2
goal of 70% or higher was targeted after central venous and mean arterial pressure goals
were met. If the ScvO2 was lower than 70% and the hematocrit was lower than 30%, packed
red blood cells were transfused to achieve a hematocrit of at least 30%. If the ScvO2
remained lower than 70% after the hematocrit was 30% or higher, dobutamine was initiated
and titrated in attempts to achieve an ScvO2 of at least 70%.
Patients randomized to the lactate clearance group received an identical central venous
catheter capable of measuring continuous ScvO2. The primary intervention consisted of the
act of not connecting the catheter to the computerized spectrophotometer thus preventing
display of ScvO2 at any time in the emergency department. These patients were cared for
according to an identical prespecified treatment plan for central venous and mean arterial
pressure targets as outlined for the ScvO2 group. However, in the lactate clearance group,
clinicians used lactate clearance instead of ScvO2 as the last resuscitation goal in the
protocol and targeted a lactate clearance of at least 10%.15,16 The lactate clearance was
defined by the equation [(lactateinitial − lactatedelayed)/lactateinitial] × 100%, for which lactate
initial was the measurement at the start of the resuscitation and lactate delayed was another
measurement after a minimum of 2 hours after resuscitation was initiated. If the lactate
clearance was not at least 10% at the first delayed measurement and the hematocrit was less
than 30%, packed red blood cells were transfused to achieve a hematocrit of at least 30%. If
the lactate clearance remained lower than 10% after the hematocrit was at least 30%,
dobutamine was initiated and titrated in attempts to achieve a lactate clearance of at least
10%. When treatment was continued due to lactate clearance less than 10%, subsequent
lactate measurements were performed at a minimum of 1-hour intervals and repeat lactate
clearance calculated. Lactate measurements were performed using venous whole blood
samples using US Food and Drug Administration–approved devices performed either at the
point of care or in the central hospital laboratory, according to participating institutional
standards.18 The lactate clearance goal was met by a lactate clearance of at least 10% or if
both the initial and delayed lactate concentrations were not elevated (≤18 mg/dL [2 mmol/
L]).
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Study patients were treated in the emergency department during the entire study treatment
period, from randomization to either of the 2 study termination criteria: all treatment goals
were achieved or 6 hours had elapsed. Patients were then transferred to an ICU where the
critical care physicians, unencumbered by the study protocol in any way, assumed the care
of all patients. The study investigators did not provide care for the patients or influence their
care in the ICU.
As a safety measure, clinical physicians could elect study group crossover. For patients
assigned to the ScvO2 group, clinicians could order a second lactate concentration to
calculate the lactate clearance. In the lactate clearance group, the clinician could request to
connect the central venous catheter to monitor ScvO2. To execute 1 of these options, the
clinician was required to indicate clinical deterioration based on 1 of the following criteria:
(1) falling systolic blood pressure or inadequate urine output (<0.5 mL/kg per hour); (2)
worsening ventilatory status based on either clinical (respiratory rate, oxygen saturation, or
oxygen requirement), arterial blood gas, or mechanical ventilator parameters; or (3)
worsened mental status. Patients for whom the clinicians enacted the study group crossover
methods were assessed using an intent-to-treat analysis of the original group assignment.
Assessments and Outcome Measures
During the study resuscitation treatment period, the patient’s physiological parameters were
measured routinely. All data needed to calculate the Simplified Acute Physiology Score
(SAPS) II,19 Sequential Organ Failure Assessment (SOFA) score,20 and the Mortality in
Emergency Department Sepsis21 were collected. After ICU admission, patients were
assessed daily for 72 hours and detailed data were collected. Patients were followed up until
hospital discharge or death.
The primary end point was absolute in-hospital mortality rate. Secondary end points were
ICU length of stay, hospital length of stay, ventilator-free days, and new onset multiple
organ failure. Other end points assessed were the number of resuscitative goals achieved,
administered treatments, and predefined protocol-related serious adverse events.
Statistical Analysis
The sample size calculation and primary analytical plan centered on the hypothesis of
noninferiority of lactate clearance vs ScvO2. For the sample size estimate, previously
published data suggested a 25% primary outcome event rate for the ScvO2 group; we
predicted no difference between the groups for the primary outcome event rate, and we set
the noninferiority margin (Δ) at −10%.22–24 The −10% margin was chosen because it
represented a two-thirds proportion of the active comparator’s (ScvO2 group) established
superiority in a similar clinical trial9 and large databases indicate that the mortality rate for
severe sepsis can be expected to vary up to 10% between both state-of-the art medical
facilities and regions of the United States.25 Using a 1-sided test of noninferiority, assuming
a control group mortality rate of 25% and α= .05, a sample size of 150 per group gave 71%
power to determine the intervention did not increase mortality by more than 10%.
When appropriate, categorical data were compared using a χ2 test or Fisher exact test and
continuous variables were compared with a Mann-Whitney U test or unpaired t test, 2-sided
with P<.05 considered significant (Stats Direct v 2.7.7, Cheshire, England). Two pre-
planned blinded interim safety analyses were performed after one-third and two-thirds of the
participants were enrolled, and these results were reviewed by an independent safety
monitor who had the authority to terminate the study for safety concerns. No sample size
adjustments were planned during the interim analyses. We planned both intent-to-treat and
per-protocol analyses after study completion.
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RESULTS
Of 452 patients who underwent screening for eligibility, 300 underwent randomization
(Figure). Of these 300 patients, the same pattern of protocol noncompletion was observed in
each group: 2 because a chest or neck central venous catheter could not be placed and 1
because family members had decided to withdraw support before the research procedure
was completed. One patient in the lactate clearance group had the crossover enacted by a
physician after all study goals had been met. The ScvO2 value in this patient was normal, so
no treatment changes were made. Because the study treatment period had ended, this patient
was analyzed in the lactate clearance group for both the intent-to-treat and per-protocol
analyses. None were lost to follow-up or voluntarily withdrew from the study, leaving 150
patients in each group for the intent-to-treat analysis and 147 in each group for the per-
protocol analysis.
The baseline characteristics of the 2 groups are shown in Table 1 and in Table 2. There were
no significant differences between the groups in demographics, comorbid conditions,
severity of illness scores, or suspected site of infection. The lungs were the most common
source of infection, and 38% of patients had a blood specimen that yielded growth of
bacteria, whereas 84% had at least 1 culture specimen that was positive. The median time
from emergency department triage to eligibility was 111 minutes (interquartile range [IQR],
56–192 minutes) in the lactate clearance group and 105 minutes (IQR, 60–175 minutes) in
the ScvO2 group (P=.67); the median time from eligibility to study entry was 14 minutes
(IQR, 1–48 minutes) in the lactate clearance group and 13 minutes (IQR, 1–55 minutes) in
the ScvO2 group (P =.72). Prior to enrollment in the study, the mean (SD) amount of
intravenous fluid administered was 2.3 L(1.4 L) in the lactate clearance group and 2.4 L (1.4
L) in the ScvO2 group (P =.37).
Table 3 shows the physiological and severity of illness variables during the first 72 hours of
hospitalization. During the first 24 hours, both groups of patients tended to show a trend
toward slightly worsening severity of illness in the form of lower systolic blood pressures
and higher SOFA scores. The mean initial lactate concentrations were 35.1 mg/dL (3.9
mmol/L) in the lactate clearance group and 37.8 mg/dL (4.2 mmol/L) in the ScvO2 group
(P=.39). The mean (SD) lactate concentration measured at 2 hours in the lactate clearance
group was 23.4 (23.3) mg/dL (2.6 [2.59] mmol/L) and the median lactate clearance at 2
hours was 40% (IQR, 18%–64%). After the initial 24 hours, survivors in both groups
manifested improvements in their physiological and severity of illness scores. We observed
that lactate measurements did not worsen over the initial 72 hours (Table 3), suggesting that
the initial lactate levels were often the most abnormal.
There were no differences in the administered treatments through the initial 72 hours of
hospitalization as shown in Table 4. During the emergency department–based 6-hour
resuscitation period, patients received approximately 4.5 L of crystalloid, 221 patients (74%;
95% confidence interval [CI], 68%–79%) required vasopressors for hypotension, and 79
patients (26%; 95% CI, 21%–32%) required mechanical ventilation. Notably, only 29
patients (10%; 95% CI, 7%–14%) required either dobutamine infusion or packed red blood
cell transfusion during the initial 6 hours of treatment. Activated protein C administration
was only administered in 5 patients (2%; 95% CI, 1%–4%).
Among the 294 (147 per group) patients included in the per-protocol analysis, the central
venous pressure goal was achieved in 133 patients (91%; 95% CI, 85%–95%) in the lactate
clearance group and 133 (91%; 95% CI, 85%–95%) in the ScvO2 group (P =.99); the mean
arterial pressure goal was achieved in 142 patients (97%; 95% CI, 92%–99%) in the lactate
clearance group and 142 (97%; 95% CI, 92%–99%) in the ScvO2 group (P=.99); and the
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lactate clearance goal was met in 139 patients (95%; 95% CI, 90%–98%) in the lactate
clearance group and the ScvO2 goal was met in 136 (93%; 95% CI, 87%–96%) patients in
the ScvO2 group (P=.67). The median time from patient triage in the emergency department
to first antibiotic administration was 115 (IQR, 62–180) minutes in the lactate clearance
group and 115 (IQR, 66–170) minutes in the ScvO2 group(P =.98).
The primary and secondary study outcome analysis is outlined in Table 5. In the intent-to-
treat analysis the inhospital mortality rate was 17% (25 of 150 [95% CI, 11%–24%]) in the
lactate clearance group compared with 23% (34 of 150 [95% CI, 17%–30%]) in the ScvO2
group. The difference in these mortality rates was 6% (95% CI, −3% to 15%). The lower
limit of this CI is well above the −10% predefined non-inferiority threshold, confirming the
primary hypothesis of noninferiority between the lactate clearance and ScvO2 groups for in-
hospital mortality. These results did not change substantially in the per-protocol analysis.
There were no differences in the observed rates of predefined protocol-related serious
adverse events between the lactate clearance (9 of 150 [6%; 95% CI, 3%–11%]) and ScvO2
(11 of 150 [7%; 95% CI, 4%–13%]) groups (P=.81).
COMMENT
The results of this large multicenter randomized controlled trial of 2 resuscitation protocols
for early sepsis resuscitation indicate that a protocol targeting lactate clearance of at least
10% as evidence of adequate tissue oxygen delivery produces a similar short-term survival
rate as a protocol using ScvO2 monitoring. Patients in the group resuscitated to a lactate
clearance of 10% or higher had 6% lower in-hospital mortality than those resuscitated to an
ScvO2 of at least 70% (95% CI for this difference, −3% to 15%) exceeding the −10%
predefined noninferiority threshold. These data support the substitution of lactate
measurements in peripheral venous blood as a safe and efficacious alternative to a
computerized spectrophotometric catheter in the resuscitation of sepsis. To our knowledge,
this is the largest randomized trial of emergency department–based early quantitative
resuscitation for sepsis conducted to date and the first such trial to investigate the relative
value of different goals of early, emergency department–resuscitation strategies.
The physiological basis for lactate clearance presumes that circulatory shock causes
inadequate oxygen delivery, resulting in mitochondrial hypoxia. Under hypoxic conditions,
mitochondrial oxidative phosphorylation fails, and energy metabolism becomes dependent
on anaerobic glycolysis.26 Anaerobic glycolysis sharply increases the production of cellular
lactate, which diffuses into the blood during prolonged cell hypoxia. In patients with a
clinical picture of severe infection, the blood lactate concentration varies in proportion to the
ongoing deficit in tissue oxygenation, and the ability of the patient to reduce the blood
lactate concentration indicates restoration of oxygen delivery with resuscitation.27 Previous
work has found that a lactate clearance of 10% or more predicts survival from septic shock,
providing the rationale for this goal.15,16 In addition, we constructed the protocol to consider
2 normal lactate levels (≤18 mg/dL [2 mmol/L]) at least 2 hours apart as evidence of
ongoing adequate tissue oxygenation. The rationale for including this criterion was that
clinically it would make no sense to attempt to clear a value that is already normal and that 2
normal values provide a reasonable clinical signal that effective resuscitation has prevented
worsening of tissue oxygenation and anaerobic metabolism.
We have previously documented that many clinicians perceive a significant degree of
technical difficulty associated with the use of computerized spectrophotometric catheters to
monitor ScvO2.28 These devices require equipment and expertise that are not available in
many tertiary care emergency departments.13 Use of ScvO2 monitoring catheters requires
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preplanned training and real-time calibration and troubleshooting that can divert attention
from the patient.28 We thus submit that the need exists for a simpler and more generalizable
method to monitor the adequacy of tissue oxygen delivery as a research imperative in the
treatment of patients with severe infection. Our results address this un-met need by
providing data that justify the use of lactate clearance instead of continuous ScvO2
monitoring.
The sample size assumed a mortality rate of 25% in the active comparator (ScvO2) group.
The observed mortality was 23% in the ScvO2 group, indicating that we maintained
approximately 80% power to detect a true difference. Although our observed overall
mortality rate (20%) is lower than the 37% overall rate reported in the sentinel emergency
department–based resuscitation study,9 it is nearly identical to mortality rates that both
individual investigators from our group22–24 and others29 have previously reported in
effectiveness studies conducted in more heterogeneous populations. We believe that that the
mortality rate represents a contemporaneous and accurate estimate of the true mortality rate
for patients with severe sepsis and septic shock treated with an early quantitative
resuscitation protocol in the emergency department.
Several limitations of our study warrant discussion. By its design, the groups could not be
blinded, allowing for possible treatment bias. Our protocol was designed with safeguards to
minimize this potential effect. For example, every participant received identical central
venous catheters so that group assignment would not be easily identifiable. Also,
investigators involved with the study were not allowed to provide care for the participants or
influence their care in the ICU. Second, we did not have a method to assess whether an
indicated therapeutic action was performed in response to a parameter below the intended
goal (eg, if central venous pressure was 4 mm Hg, we did not record whether a fluid bolus
was given). Rather, we only assessed for compliance with individual treatment goals during
the study treatment period. Third, this study was conducted at 3 institutions that had
established emergency department–based quantitative resuscitation programs for sepsis prior
to initiation of the study. Therefore, our results may not be generalizable to centers that do
not routinely perform early quantitative resuscitation. Fourth, if other influences on care
were ignored, it could be suggested that the potential difference in protocol actions directly
attributable to using lactate clearance vs ScvO2 was small, because only 10% of patients
went on to receive dobutamine or packed red blood cell transfusion. Fifth, we did not have a
mechanism to query ICU admission for potentially missed cases; thus, we may have missed
patients who met criteria because a clinical alert was not activated. Finally, it is possible that
knowledge of the study prompted clinical care providers to have a heightened awareness and
provide differential treatment patterns (ie, a Hawthorne-like effect).
In conclusion, in this randomized trial, we found no difference in mortality for patients with
severe sepsis and septic shock resuscitated with a protocol that used lactate clearance
compared with a protocol that used ScvO2 as the method of measuring total body oxygen
metabolism.
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Figure.
Study Flow Diagram
ScvO2 indicates central venous oxygen saturation.
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Table 1
Patient Demographics and Clinical Characteristicsa
Variable
No. (%) of Patients
Lactate Clearance Group (n = 150) ScvO2 Group (n = 150)
Age, mean (SD), y 59.8 (17.6) 61.6 (17.6)
Race
 White
88 (59) 77 (51)
 Black 47 (31) 56 (37)
Sex
 Men
83 (55) 80 (53)
 Women 67 (45) 70 (47)
Comorbidities
 Diabetes mellitus
45 (30) 57 (38)
 Chronic obstructive pulmonary disease 25 (17) 25 (17)
 Human immunodeficiency virus infection 12 (8) 13 (9)
 End-stage renal disease 15 (10) 14 (9)
 Active malignancy 42 (28) 32 (21)
 Organ transplant 5 (3) 4 (6)
 Indwelling vascular line 6 (4) 10 (7)
 Nursing home resident 28 (19) 28 (19)
Disease severity
 SAPS II score
44.8 (18.4) 44.1 (17.3)
 SOFA score 6.7 (3.6) 6.6 (3.5)
 MEDS score 10.9 (3.9) 10.6 (3.4)
Suspected source of infection
 Pulmonary
48 (32) 54 (36)
 Urinary tract 40 (27) 39 (26)
 Intra-abdominal 34 (23) 24 (16)
 Skin/soft tissue 19 (13) 23 (15)
 Blood 8 (5) 9 (6)
 Unknown 13 (9) 9 (6)
Features of sepsis
 Lactate ≥4
61 (41) 56 (37)
 Shockb 121 (81) 123 (82)
 Culture positive 123 (82) 127 (85)
 Blood culture positive 62 (41) 53 (35)
 Gram positive 33 (22) 36 (24)
 Gram negative 29 (19) 17 (11)
Abbreviations: MEDS, mortality in emergency department sepsis; SAPS, Simplified Acute Physiology Score; ScvO2, central venous oxygen
saturation; SOFA, Sequential Organ Failure Assessment.
a
Continuous data are compared using an unpaired t test; categorical data, using the χ2 test.
b
Shock is defined as a systolic blood pressure of 90 mm Hg or less after receiving a 20 mL/kg-fluid bolus.
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Table 2
Systemic Inflammatory Response Criteria and Dysfunctional Organ Systems
Variable
No. (%) of Patients
Lactate Clearance Group (n = 150) ScvO2 Group (n = 150)
SIRS criteria
 Abnormal white blood cell count
117 (78) 104 (69)
 Elevated heart rate 100 (67) 108 (72)
 Elevated respiratory rate 96 (64) 89 (59)
 Abnormal body temperature 61 (41) 64 (43)
Organ dysfunction
 Respiratory
85 (57) 86 (57)
 Liver 43 (29) 43 (29)
 Neurological 47 (31) 58 (39)
 Coagulation 51 (34) 39 (26)
 Cardiovascular 132 (88) 128 (85)
 Renal 110 (73) 109 (73)
Abbreviations: ScvO2, central venous oxygen saturation; SIRS, systemic inflammatory response syndrome.
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Table 3
Physiological and Severity of Illness Measurements
Variable by Study Time Point, ha Lactate Clearance Group (n = 150) ScvO2 Group (n = 150) P Valueb
Systolic blood pressure, mm Hg
 0
91 (24.6) 92 (21.0) .62
 24 73 (20.8) 79 (15.3) .01
 48 94 (22.1) 95 (21.3) .91
 72 103 (19.9) 103 (19.1) .87
Heart rate, beats/min
 0
103 (23.6) 106 (24.4) .36
 24 117 (23.6) 119 (21.9) .37
 48 106 (19.7) 107 (20.5) .51
 72 105 (22.1) 103 (20.1) .56
Central venous pressure, mm Hg
 0
11 (6.5) 11 (6.2) .55
 24 16 (7.8) 15 (6.6) .47
 48 13 (6.4) 14 (6.5) .45
 72 12 (6.5) 14 (8.3) .14
Central venous oxygen saturation, %
 0
74 (12.3)
 24 65 (19.9) 64 (13.1) .71
 48 70 (16.6) 68 (14.8) .53
 72
Lactate level, mg/dLc
 0
35.1 (28.1) 37.8 (27.7) .39
 24
 48
 72 35.1 (30.3) 36.9 (29.6) .67
SOFA score, median (IQR)
 0
6 (4–9) 6 (4–9) .71
 24 8 (5–11) 7 (5–11) .98
 48 4 (2–7) 5 (2–7) .90
 72 3 (1–6) 3 (1–6) .62
SAPS II score
 0
44.8 (18.4) 44.1 (17.3) .69
 24
 48
 72 33.4 (14.1) 34.6 (17.2) .54
MEDS score
 0
10.9 (3.9) 10.6 (3.4) .46
 24
 48
 72 8.4 (4.2) 8.4 (4.5) .93
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Variable by Study Time Point, ha Lactate Clearance Group (n = 150) ScvO2 Group (n = 150) P Valueb
Glasgow coma scale
 0
13 (4.1) 13 (3.7) .67
 24 12 (4.3) 12 (3.9) .68
 48 13 (3.7) 13 (3.5) .91
 72 15 (3.1) 14 (4.0) .04
Abbreviations: IQR, interquartile range; MEDS, Mortality in Emergency Department Sepsis; SAPS, Simplified Acute Physiology Score; ScvO2,
central venous oxygen saturation; SOFA, Sequential Organ Failure Assessment.
SI conversion factor: to convert lactate concentration from mg/dL to mmol/L, multiply by 0.111.
a
Values represent the mean (SD) measurements at enrollment (0) and the most abnormal values at each hour of measurement, except for the SOFA
score. Lactate values and SAPS and MEDS scores were not recorded at 24 and 48 hours.
b
Continuous data are compared using an unpaired t test; categorical variables, using the χ2 test.
c
Lactate levels at 72 hours represent worst value over the initial 72 hours of hospitalization.
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Table 4
Administered Treatments and Resuscitation Goals
Intervention, h
No. (%) of Patients
P ValueaLactate Clearance Group (n = 150) ScvO2 Group (n = 150)
Crystalloid volume, mean (SD), L
 0-<6
4.5 (2.36) 4.3 (2.21) .55
 6–72 12.4 (6.15) 11.8 (6.41) .44
Vasopressor administration
 0-<6
108 (72) 113 (75) .60
 6–72 100 (67) 108 (72) .45
Dobutamine administration
 0-<6
5 (3) 8 (5) .57
 6–72 10 (7) 13 (9) .66
PRBC transfusion
 0-<6
11 (7) 5 (3) .20
 6–72 35 (23) 31 (21) .78
Mechanical ventilation
 0-<6
40 (27) 39 (26) .99
 6–72 69 (46) 75 (50) .56
Activated protein C
 0-<6
0 0
 6–72 3 (2) 2 (1) .68
Parenteral corticosteroids
 0-<6
18 (12) 26 (17) .25
 6–72 59 (39) 51 (34) .40
Abbreviations: PRBC, packed red blood cell; ScvO2, central venous oxygen saturation.
a
Continuous variables are compared using unpaired t test; categorical variables, using χ2 test except activated protein C which was analyzed using
Fisher exact test.
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Table 5
Hospital Mortality and Length of Stay
Variable
Lactate Clearance Group (n
= 150) ScvO2 Group (n = 150)
Proportion Difference (95%
Confidence Interval) P Valueb
In-hospital mortality, No. (%)a
 Intent to treat
25 (17) 34 (23) 6 (−3 to 15)
 Per protocol 25 (17) 33 (22) 5 (−3 to 14)
Length of stay, mean (SD), d
 ICU
5.9 (8.46) 5.6 (7.39) .75
 Hospital 11.4 (10.89) 12.1 (11.68) .60
Hospital complications
 Ventilator-free days, mean (SD)
9.3 (10.31) 9.9 (11.09) .67
 Multiple organ failure, No. (%) 37 (25) 33 (22) .68
 Care withdrawn, No. (%) 14 (9) 23 (15) .15
Abbreviations: ICU, intensive care unit; ScvO2, central venous oxygen saturation.
a
Primary study end point.
b
Continuous data are compared using an unpaired t test; categorical variables, using the χ2 test.
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